ANAB

70.22

2.17% 1.49

Pre-mercato: 69.84 -0.38 -0.54%

Anaptysbio Inc (ANAB)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$68.73

Aprire:

$69

Volume 24 ore:

425.44K

Relative Volume:

0.78

Capitalizzazione di mercato:

$2.02B

Reddito:

$234.60M

Utile/perdita netta:

$-13.23M

Rapporto P/E:

-134.88

EPS:

-0.5206

Flusso di cassa netto:

$19.61M

1 W Prestazione:

+13.02%

1M Prestazione:

+8.35%

6M Prestazione:

+120.47%

1 anno Prestazione:

+293.17%

Intervallo 1D:

$66.14

$71.29

Intervallo di 1 settimana:

$62.72

$73.30

Portata 52W:

$17.11

$73.30

Anaptysbio Inc Stock (ANAB) Company Profile

Nome

Anaptysbio Inc

Settore

Healthcare (1110)

Industria

Biotechnology (622)

Telefono

858-362-6295

Indirizzo

10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA

Dipendente

104

Cinguettio

@anaptysbio

Prossima data di guadagno

2024-11-08

Ultimi documenti SEC

ANAB's Discussions on Twitter

Compare ANAB vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
ANAB Anaptysbio Inc	70.22	2.02B	234.60M	-13.23M	19.61M	-0.5206
VRTX Vertex Pharmaceuticals Inc	444.28	110.97B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	755.51	79.17B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	828.35	49.73B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	339.41	42.98B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	310.00	34.37B	5.36B	287.73M	924.18M	2.5229

Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-07	Ripresa	UBS	Buy
2025-10-13	Iniziato	Barclays	Overweight
2025-06-04	Aggiornamento	H.C. Wainwright	Neutral → Buy
2025-02-04	Iniziato	Wolfe Research	Outperform
2024-12-11	Downgrade	H.C. Wainwright	Buy → Neutral
2024-12-02	Downgrade	BTIG Research	Buy → Neutral
2024-07-22	Iniziato	H.C. Wainwright	Buy
2024-07-19	Aggiornamento	JP Morgan	Neutral → Overweight
2024-04-16	Iniziato	Leerink Partners	Outperform
2024-04-11	Iniziato	Wells Fargo	Overweight
2024-03-12	Aggiornamento	Wedbush	Neutral → Outperform
2024-02-26	Iniziato	BTIG Research	Buy
2024-02-21	Iniziato	Stifel	Buy
2024-02-16	Iniziato	Piper Sandler	Overweight
2023-05-22	Aggiornamento	JP Morgan	Underweight → Neutral
2023-05-18	Iniziato	TD Cowen	Outperform
2023-01-06	Downgrade	Raymond James	Outperform → Mkt Perform
2022-11-01	Aggiornamento	Guggenheim	Neutral → Buy
2022-09-19	Ripresa	H.C. Wainwright	Buy
2022-09-13	Downgrade	Truist	Buy → Hold
2022-09-01	Iniziato	Raymond James	Outperform
2022-03-22	Downgrade	Guggenheim	Buy → Neutral
2021-06-22	Iniziato	H.C. Wainwright	Buy
2021-05-21	Iniziato	UBS	Neutral
2021-03-16	Aggiornamento	Truist	Hold → Buy
2021-03-09	Downgrade	Wedbush	Outperform → Neutral
2021-03-08	Downgrade	JP Morgan	Overweight → Underweight
2021-02-11	Aggiornamento	JP Morgan	Underweight → Overweight
2020-10-27	Aggiornamento	Wedbush	Neutral → Outperform
2020-10-14	Aggiornamento	Guggenheim	Neutral → Buy
2019-11-08	Downgrade	JP Morgan	Overweight → Underweight
2019-11-08	Downgrade	Jefferies	Buy → Hold
2019-11-08	Downgrade	SunTrust	Buy → Hold
2019-11-08	Downgrade	Wedbush	Outperform → Neutral
2019-06-21	Downgrade	Credit Suisse	Outperform → Neutral
2019-06-21	Downgrade	Stifel	Buy → Hold
2018-12-20	Iniziato	H.C. Wainwright	Buy
2018-11-21	Iniziato	JP Morgan	Overweight
2018-07-19	Iniziato	Credit Suisse	Outperform
2018-04-04	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2018-03-27	Reiterato	Stifel	Buy
2018-03-06	Reiterato	Stifel	Buy
2018-02-15	Reiterato	SunTrust	Buy
2018-01-23	Reiterato	Credit Suisse	Outperform
2017-11-15	Iniziato	SunTrust	Buy
2017-11-09	Iniziato	Jefferies	Buy
2017-10-11	Reiterato	RBC Capital Mkts	Outperform
2017-09-15	Iniziato	RBC Capital Mkts	Outperform

Mostra tutto

Anaptysbio Inc Borsa (ANAB) Ultime notizie

Apr 14, 2026

JPMorgan Chase Reduces Stake in AnaptysBio Biotech Firm - National Today

Apr 14, 2026